Heather Dealy, MD
Ophthalmology · Wilmington, DENPI 1265424170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- AbbVie$906
- Alcon$581
- Bausch & Lomb, A Division Of Bausch Health US, LLC$389
- Bausch & Lomb Americas Inc.$387
- NEW World Medical,inc.$321
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,82996%
- Education$1963%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 40 | $1,369 |
| AbbVie(2 entities) | 49 | $906 |
| Alcon | 26 | $581 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $389 |
| Bausch & Lomb Americas Inc. | 22 | $387 |
| NEW World Medical,inc. | 3 | $321 |
| Sun Pharmaceutical Industries Inc. | 10 | $250 |
| Harrow Eye, LLC | 10 | $229 |
| Biotissue Holdings Inc. | 3 | $193 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $192 |
| Glaukos Corporation | 5 | $165 |
| Sight Sciences, Inc. | 3 | $137 |
| Genentech USA, Inc. | 1 | $114 |
| Aerie Pharmaceuticals, Inc. | 6 | $110 |
| Tarsus Pharmaceuticals, Inc. | 4 | $85 |
| Novartis | 4 | $83 |
| Kala Pharmaceuticals, Inc. | 3 | $83 |
| Oyster Point Pharma, Inc. | 3 | $71 |
| Coopervision Inc. | 3 | $66 |
| Dompe US, Inc. | 2 | $61 |
| Amgen | 3 | $53 |
| Rxsight Inc | 2 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Topcon Healthcare, Inc. | 1 | $30 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| Carl Zeiss Meditec AG | 1 | $17 |
| Thea Pharma Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Oasis Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,042 in reported general payments places this provider in the 90th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 194 | $100,768 |
| RestasisCyclosporine | 26 | $25,544 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 89 | $20,775 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $16,433 |
| CombiganBrimonidine Tartrate/Timolol | 22 | $15,012 |
| Prednisolone Acetate | 239 | $12,084 |
| Latanoprost | 861 | $10,118 |
| RhopressaNetarsudil Mesylate | 19 | $9,639 |
| Brimonidine Tartrate | 237 | $9,005 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $8,323 |
| Alphagan PBrimonidine Tartrate | 17 | $8,036 |
| Travoprost | 47 | $7,530 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 36 | $7,287 |
| VyzultaLatanoprostene Bunod | 14 | $6,464 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 310 | $6,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $906 | $149,360259 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $110 | $26,07241 claims |
| AlconSimbrinza | $581 | $8,32324 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $387 | $6,46414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Wilmington
- Jeffrey MinkovitzWilmington$7K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Michael BrosmanWilmington$5K
- Brian ToussaintWilmington$2K
- Sean ConsidineWilmington$2K
- Tabassum AliWilmington$2K
- Paula KoWilmington$2K
- Harry LebowitzWilmington$2K
- Charles WangWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.